Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 2/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11832147 | 0.82 | OPRL1 (0.54) | OPRL1POLBCCR3LTA4H | |
| SCHEMBL4229239 | 0.82 | HRH3 (0.44) | OPRL1CCR3KDM4E | |
| SCHEMBL3890625 | 0.79 | OPRL1 (0.82) | OPRL1POLBCCR3DRD4KDM4E | |
| SCHEMBL18715834 | 0.79 | MEN1 (0.48) | LTA4HDRD4KMT2ADRD2DRD3 | |
| SCHEMBL6169096 | 0.78 | ALDH1A1 (0.47) | DRD4KDM4EKMT2ADRD2DRD3 | |
| SCHEMBL11835351 | 0.78 | OPRL1 (0.46) | OPRL1POLBCCR3LTA4HKDM4E | |
| SCHEMBL4229650 | 0.78 | HRH3 (0.43) | OPRL1KDM4E | |
| SCHEMBL7274935 | 0.78 | HRH3 (0.38) | KDM4E | |
| SCHEMBL11844790 | 0.77 | OPRL1 (0.45) | OPRL1POLBCCR3 | |
| SCHEMBL1411499 | 0.76 | OPRL1 (1.00) | OPRL1POLBCCR3LTA4HDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960238-B1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2960238-B1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2960238-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-2960238-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-8933099-B2 | Monocyclic pyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933099-B2 | Monocyclic pyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933099-B2 | Monocyclic pyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| WO-2014129477-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2014-08-28 | — | — | WO | disclosed |
| US-20140235614-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140235614-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140235614-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | OPRL1 19/4885POLB 4249/4885CCR3 1438/4885 |
| US-20140235614-A1 | MONOCYCLIC PYRIDINE DERIVATIVE | FGFR2, FGFR1, FGFR3 | OPRL1 836/4885POLB 4610/4885CCR3 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.